CT-1812 is under clinical development by Cognition Therapeutics and currently in Phase II for Dry (Atrophic) Macular Degeneration. According to GlobalData, Phase II drugs for Dry (Atrophic) Macular Degeneration does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CT-1812 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CT-1812 overview

CT-1812 (CT-018120, Elayta) is under development for the treatment of mild to moderate Alzheimer's disease, Parkinson’s disease, lewy body dementia and geographic atrophy (GA) and dry age-related macular degeneration (dry AMD). It is administered orally in form of capsule. It is a small molecule which acts by targeting sigma-2/PGRMC1 and Abeta (Amyloid Beta Peptide) oligomers.

Cognition Therapeutics overview

Cognition Therapeutics (CogRx) is a drug discovery and development company. It discovers and develops small molecule therapeutics for Alzheimer’s disease and other neurocognitive disorders. The company uses its proprietary biology and chemistry platforms for the development of novel drug targets and disease-modifying therapies for the treatment of central nervous system disorders. It conducts clinical trials on its drug candidate CT1812 for the treatment of Alzheimer’s disease. The company uses screening strategy to identify small molecules capable of blocking the central toxicity of soluble oligomeric proteins. CogRx is headquartered in Purchase, New York, the US.

For a complete picture of CT-1812’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.